Potential years of life and productivity loss due to malignant mesothelioma in Turkey

Metintaş, Selma; Ak, Güntülü; Metintaş, Muzaffer

doi:10.1080/19338244.2020.1747380

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased use of surgery explains at least in part the increased cost per admission. Several studies investigated the social burden of mesothelioma, someone focused on years of life lost and years of potential life lost 30 others (like this) on the hospitalisation cost. [31][32][33][34][35] Even if direct comparisons are not possible because of different economies and financial management of hospitals between countries, we have found very similar ratios between mean hospital costs by surgical procedures with a recent American work 35 (table 2).…”

Section: Discussionmentioning

confidence: 99%

Hospitalisation costs of malignant mesothelioma: results from the Italian hospital discharge registry (2001–2018)

Ferrante

2021

BMJ Open

View full text Add to dashboard Cite

ObjectivesThis paper aims to establish hospitalisation costs of mesothelioma in Italy and to evaluate hospital-related trends associated with the 1992 asbestos ban.DesignThis is a retrospective population-based study of Italian hospitalisations treating pleura, peritoneum and pericardium mesothelioma in the period 2001–2018.SettingsPublic and private Italian hospitals reached by the Ministry of Health (coverage close to 100%).Participants157 221 admissions with primary or contributing diagnosis of pleural, peritoneal or hearth cancer discharged from 2001 to 2018.Primary and secondary outcome measures: number, length and cost of hospitalisations with related percentages.ResultsEach year, Italian hospitals treated a mesothelioma in 6025 admissions on average. Mean annual costs by site were €20 293 733, €3183 632 and €40 443 for pleura, peritoneum and pericardium, respectively. Pericardial mesothelioma showed the highest cost per admission (€6117), followed by peritoneal (€4549) and pleural cases (€3809). Percentage of hospitalisation costs attributable to mesothelioma was higher when it is located in pleura (53.4%) and pericardium (51.8%) with respect to peritoneum (41.2%). Overall annual hospitalisation cost, percentages of number and length of admissions showed an inverted U-shape, with maxima (of €25 850 276, 0.064% and 0.096%, respectively) reached in 2011–2013. Mean age at discharge and percentages of surgery and of urgent cases increased over time.ConclusionsThe highest impact of mesothelioma on the National Health System was recorded 20 years after the asbestos ban (2011–2013). Hospitals should expect soon fewer but more severe patients needing more cares. To study the disease prevalence could help assistance planning of next decade.

show abstract

Section: Discussionmentioning

confidence: 99%

Hospitalisation costs of malignant mesothelioma: results from the Italian hospital discharge registry (2001–2018)

Ferrante

2021

BMJ Open

View full text Add to dashboard Cite

show abstract

“…Therefore, even in the present era, when the use of asbestos is banned, the number of deaths from MM in the world is estimated to continue to increase, and it is thought that the number of deaths will reach its peak in Japan, for example, from 2030 to 2034 [ 1 ]. Because of the limited treatment options, survival time and cost, MM is a major problem throughout the world [ 4 ]. Therefore, research leading to the early diagnosis and early treatment of MM is important.…”

Section: Introductionmentioning

confidence: 99%

Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor

et al. 2022

View full text Add to dashboard Cite

Although the routine use of immunohistochemistry has improved the accuracy of histopathologic diagnosis in clinical practice, new methods for discovering novel diagnostic markers are still needed. We sought new diagnostic markers for malignant pleural mesothelioma (MPM) using a reverse translational approach with limited archival tissues from a very rare case. Total RNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues of a synchronous collision tumor consisting of MPM and pulmonary adenocarcinoma (PAC) was employed for gene expression profiling (GEP) analysis. Among the 54 genes selected by GEP analysis, we finally identified the following two candidate MPM marker genes: PHGDH and TRIM29. Immunohistochemical analysis of 48 MM and 20 PAC cases showed that both PHGDH and TRIM29 had sensitivity and specificity almost equivalent to those of calretinin (sensitivity 50% and 46% vs. 63%, and specificity 95% and 100% vs. 100%, respectively). Importantly, of the 23 epithelioid MMs, all 3 calretinin-negative cases were positive for TRIM29. These two markers may be diagnostically useful for immunohistochemical distinction between MPMs and PACs. This successful reverse translational approach based on FFPE samples from one very rare case encourages the further use of such samples for the development of novel diagnostic markers.

show abstract

“…5 As known, pleural effusion sampling is minimally invasive, inexpensive, and does not require anesthesia. Therefore, using pleural effusion material in the definitive diagnosis of mesothelioma becomes even more imperative for our center 10 Based on this reason, our aim in this study is to evaluate the diagnostic importance of MTAP and BAP1 stain loss (IHC), p16 homozygous deletion (FISH) in cell blocks obtained from pleural effusion materials of mesothelioma patients proven by tissue biopsy and to evaluate the superiority of these methods over each other.…”

mentioning

confidence: 99%

Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma

Şeker,

Tekin,

et al. 2024

Diagnostic Cytopathology

View full text Add to dashboard Cite

BackgroundMesothelioma is a malignant neoplasm with a poor survival rate. We aimed to investigate the importance of BAP1, MTAP (IHC), and p16/CDKN2A homozygous deletion (FISH) in cytologic material obtained from pleural effusion sampling, which is a less invasive procedure in the diagnosis of mesothelioma.MethodsOur study discussed pleural cytology samples of cases with histopathologically proven mesothelioma diagnoses between 2017 and 2022. As the control group, materials that had pleural effusion sampling for other reasons and reactive mesothelial hyperplasia were included in the study. Cell blocks prepared from these materials were subjected to fluorescent in situ hybridization for p16/CDKN2A homozygous deletion and immunohistochemistry for BAP1 and MTAP.ResultsThe specificity of the P16/CDKN2A homozygous deletion in diagnosing mesothelioma is 100%. Its sensitivity is 68.75%. The specificity of BAP1 immunohistochemical nuclear expression loss is 95%, while the sensitivity is 60%. Loss of nuclear expression of MTAP alone has the lowest specificity and sensitivity, with a specificity of 86% and a sensitivity of 43%. The highest sensitivity is reached when BAP1 loss and p16/CDKN2A homozygous deletion are evaluated together, increasing to 81%. The specificity is 95%.ConclusionIt has been determined that any marker alone cannot be used for a definitive mesothelioma diagnosis in pleural effusion cytological specimens; however, sensitivity increases in some combinations. The combination of BAP1 immunohistochemistry and p16/CDKN2A homozygous deletion detected by FISH, which has a higher specificity and sensitivity, can be routinely used in the diagnosis of mesothelioma under the guidance of clinical and radiologic information.

show abstract

Potential years of life and productivity loss due to malignant mesothelioma in Turkey

Cited by 6 publications

References 25 publications

Hospitalisation costs of malignant mesothelioma: results from the Italian hospital discharge registry (2001–2018)

Hospitalisation costs of malignant mesothelioma: results from the Italian hospital discharge registry (2001–2018)

Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor

Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma

Contact Info

Product

Resources

About